Investigation for efficacy and safety of [18F] C05-05
- Conditions
- Dementia with Lewy bodies, Parkinson's disease, and multiple system atrophyD020961, D010300, D019578
- Registration Number
- JPRN-jRCTs031220123
- Lead Sponsor
- Endo Hironobu
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 91
(A) Brain dynamics evaluation
Patients (20 patients with dementia with Lewy bodies, 20 patients with Parkinsons disease, 10 patients with multiple system atrophy, 5 patients with progressive supranuclear palsy, 5 patients with corticobasal syndrome, and 5 patients with Alzheimers disease)
(1)Patients who are 20 years old or older at the time of consent acquisition.
(2)Patients whom a potential substitute can accompany on the day of participation in the study at QST
(3)Patients with dementia with Lewy bodies and Parkinsons disease: Patients who meet the UKPDSBB clinical diagnostic criteria or the diagnostic criteria of McKeith et al.
(4)Patients with multiple system atrophy: Patients who meet Gilmans clinical diagnosis criteria.
(5)patients with progressive supranuclear palsy: Patients who meet the diagnostic criteria of Hoeglinger et al and Kanazawa et al.
(6)patients with corticobasal syndrome: Patients who meet the clinical diagnostic criteria of Mayo and/or Cambridge.
(7)patients with Alzheimers disease: Patients who meet the NINCDS-ADRDA diagnostic criteria.
Healthy subjects (20 healthy subjects)
(1)Healthy adults who have been determined to be eligible for this study by the principal investigator or sub-investigator.
(2)Those who are 20 years of age or older at the time of obtaining consent.
(B) Whole body dynamic evaluation (6 Healthy subjects; 3 male and 3 female)
(1)Healthy adults who are judged to be eligible for this study by a medical examination by the principal investigator or sub-investigator.
(2)Healthy adults who are 50 years of age or older at the time consent is obtained.
(1) Patients with a history of or complications from organic brain disease (for example, disorders of consciousness, head trauma requiring hospitalization, evident cerebral infarction, or cerebral hemorrhage).
(2) Patients with substance-related disorders (for example, drug dependence).
(3) Those who have complications from serious diseases or those who have a history of such diseases, judged by the principal investigator or sub-investigator to be inappropriate for this study.
(4) Those who have magnetic metals in their body (for example, tattoos, tattoos including art makeup, pacemakers) (for brain dynamics evaluation only).
(5) Persons with intense claustrophobia.
(6) Those who are pregnant or may be pregnant, and those who are breast-feeding.
(7) Those who are allergic to local anesthetics and blood coagulation inhibitors. (Brain dynamics evaluation only)
(8) Those who are taking the anticoagulant medication. (Brain dynamics evaluation only)
(9) Others judged by the principal investigator or sub-investigator to be inappropriate as research subjects.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (A) Brain dynamics evaluation<br>Efficacy evaluation: Quantitative evaluation of the brain dynamics of [18F]C05-05 and the extent and distribution of alpha-synuclein lesions in patients with dementia with Lewy bodies, Parkinsons disease, multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome, Alzheimers disease, and healthy volunteers. Safety evaluation: Changes in subjective symptoms, other findings, and laboratory tests after [18F]C05-05 administration. <br>(B) Whole body dynamic evaluation<br>Efficacy evaluation: Distribution test of [18F]C05-05 in the whole body.<br>Safety evaluation: Effective dose per unit dose of radiation of [18F]C05-05. Changes in subjective symptoms, other findings, and laboratory tests after [18F]C05-05 administration.
- Secondary Outcome Measures
Name Time Method A) Brain dynamics evaluation<br>In patients with dementia with Lewy bodies, Parkinsons disease, multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome, Alzheimers disease, and healthy volunteers, we will explore the relationship between (1) the extent and distribution of alpha-synuclein lesions assessed by PET using [18F]C0505, (2) abnormal protein accumulation in the brain assessed by PET using [11C]PiB and [18F]PM-PBB3, (3) Brain structure and neurotransmission function assessed by MRI scan, (4) Correlation between blood data and clinical symptom scores. (2)-(4) will also be evaluated using existing data.